Profile data is unavailable for this security.
About the company
Neurocrine Biosciences, Inc. is a neuroscience-focused, biopharmaceutical company. The Company is engaged in discovering and developing treatments for patients with under-addressed neurological, neuroendocrine and neuropsychiatric disorders. Its diverse portfolio includes the United States Food and Drug Administration-approved treatments for tardive dyskinesia, chorea associated with Huntington’s disease, endometriosis and uterine fibroids, as well as a robust pipeline, including multiple compounds in mid-to late-phase clinical development across its core therapeutic areas. Its commercial products include INGREZZA, ALKINDI, EFMODY, Orilissa and Oriahnn. INGREZZA is marketed as DYSVAL (valbenazine) in Japan and REMLEAS (valbenazine) in other select Asian markets, where Mitsubishi Tanabe Pharma Corporation retains commercialization rights. ALKINDI is marketed as ALKINDI SPRINKLE (hydrocortisone) in the United States, where Eton Pharmaceuticals, Inc. retains commercialization rights.
- Revenue in USD (TTM)1.89bn
- Net income in USD249.70m
- Incorporated1996
- Employees1.40k
- LocationNeurocrine Biosciences Inc6027 EDGEWOOD BEND COURTSAN DIEGO 92130United StatesUSA
- Phone+1 (858) 617-7600
- Fax+1 (858) 617-7602
- Websitehttps://www.neurocrine.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Legend Biotech Corp (ADR) | 285.14m | -518.25m | 9.41bn | 1.80k | -- | 7.52 | -- | 32.99 | -2.95 | -2.95 | 1.62 | 6.88 | 0.1794 | 9.68 | 5.70 | 158,412.80 | -32.60 | -37.71 | -38.89 | -47.19 | 49.42 | -- | -181.75 | -286.51 | 6.83 | -24.23 | 0.208 | -- | 143.70 | 42.15 | -16.11 | -- | 1.57 | -- |
| Catalent Inc | 4.10bn | -1.30bn | 10.14bn | 17.80k | -- | 2.75 | -- | 2.47 | -7.18 | -7.18 | 22.52 | 20.37 | 0.3878 | 4.09 | 3.00 | 230,224.70 | -12.32 | 2.88 | -14.02 | 3.26 | 17.94 | 31.03 | -31.77 | 6.35 | 1.71 | -0.625 | 0.5758 | 0.00 | -11.22 | 11.59 | -153.00 | -- | 26.69 | -- |
| BIO-TECHNE Corp | 1.14bn | 224.12m | 10.30bn | 3.05k | 47.26 | 5.24 | 30.80 | 8.99 | 1.39 | 1.39 | 7.09 | 12.50 | 0.4495 | 2.21 | 5.84 | 375,409.50 | 8.80 | 9.57 | 9.28 | 10.20 | 67.13 | 67.35 | 19.58 | 21.91 | 3.03 | 18.86 | 0.1854 | 24.19 | 2.81 | 12.07 | 4.88 | 25.13 | 12.81 | 0.00 |
| Natera Inc | 1.08bn | -434.80m | 10.92bn | 3.28k | -- | 14.13 | -- | 10.09 | -3.80 | -3.80 | 9.41 | 6.40 | 0.7634 | 15.49 | 4.14 | 329,851.00 | -30.66 | -36.17 | -39.20 | -46.60 | 45.52 | 45.88 | -40.16 | -56.15 | 3.96 | -- | 0.3219 | -- | 31.99 | 33.26 | 20.63 | -- | 58.81 | -- |
| United Therapeutics Corporation | 2.33bn | 984.80m | 11.06bn | 1.17k | 11.86 | 1.85 | 10.66 | 4.75 | 19.82 | 19.82 | 46.83 | 127.23 | 0.3523 | 2.41 | 9.32 | 1,992,723.00 | 14.91 | 10.38 | 16.33 | 11.27 | 88.94 | 91.47 | 42.31 | 29.25 | 4.28 | -- | 0.1047 | 0.00 | 20.20 | 7.41 | 35.40 | 10.89 | 4.55 | -- |
| Sarepta Therapeutics Inc | 1.24bn | -535.98m | 11.10bn | 1.31k | -- | 12.90 | -- | 8.93 | -6.15 | -6.15 | 13.46 | 9.17 | 0.389 | 0.5708 | 4.04 | 946,222.30 | -16.77 | -21.63 | -20.94 | -25.75 | 87.91 | 86.65 | -43.11 | -77.05 | 3.45 | -- | 0.5903 | -- | 33.26 | 32.80 | 23.81 | -- | 6.30 | -- |
| Exact Sciences Corp | 2.50bn | -204.15m | 11.86bn | 6.50k | -- | 3.77 | 4,824.34 | 4.75 | -1.14 | -1.14 | 13.81 | 17.34 | 0.3937 | 5.32 | 13.82 | 384,579.40 | -3.22 | -9.71 | -3.47 | -10.60 | 73.83 | 74.10 | -8.17 | -28.21 | 2.07 | -- | 0.4311 | -- | 19.93 | 40.63 | 67.26 | -- | -3.71 | -- |
| Medpace Holdings Inc | 1.89bn | 282.62m | 11.99bn | 5.90k | 43.62 | 21.25 | 38.80 | 6.36 | 8.87 | 8.87 | 59.24 | 18.22 | 1.25 | -- | 6.84 | 319,634.30 | 18.80 | 13.94 | 44.16 | 23.18 | 27.81 | 28.84 | 15.00 | 15.23 | -- | 690.22 | 0.00 | -- | 29.17 | 21.76 | 15.26 | 31.17 | 17.99 | -- |
| Incyte Corp | 3.70bn | 597.60m | 12.00bn | 2.52k | 20.21 | 2.31 | 17.64 | 3.25 | 2.64 | 2.64 | 16.36 | 23.14 | 0.5855 | 4.43 | 5.32 | 1,464,203.00 | 9.47 | 9.07 | 11.69 | 11.02 | 93.71 | 94.97 | 16.17 | 13.68 | 3.69 | -- | 0.0062 | 0.00 | 8.87 | 14.45 | 75.42 | 40.41 | -15.06 | -- |
| Charles River Lbrtrs ntrntl Inc | 4.13bn | 474.62m | 12.15bn | 20.00k | 25.56 | 3.37 | 15.30 | 2.94 | 9.23 | 9.23 | 80.25 | 70.06 | 0.5228 | 8.19 | 5.39 | 206,470.50 | 6.08 | 6.46 | 7.09 | 7.62 | 36.89 | 36.99 | 11.63 | 11.58 | 1.16 | 4.97 | 0.4203 | 0.00 | 3.86 | 12.75 | -2.39 | 16.69 | 17.86 | -- |
| Neurocrine Biosciences, Inc. | 1.89bn | 249.70m | 13.25bn | 1.40k | 54.18 | 5.83 | 48.89 | 7.02 | 2.43 | 2.43 | 18.84 | 22.61 | 0.6716 | 1.08 | 4.78 | 1,347,929.00 | 8.89 | 9.77 | 11.28 | 12.19 | 97.90 | 98.51 | 13.23 | 14.79 | 2.40 | -- | 0.0708 | -- | 26.76 | 33.13 | 61.62 | 63.90 | 2.67 | -- |
| Viatris Inc | 15.43bn | 54.70m | 13.44bn | 38.00k | 267.42 | 0.6641 | 4.81 | 0.8714 | 0.0423 | 0.0423 | 12.81 | 17.05 | 0.3158 | 2.49 | 5.09 | 405,971.10 | 0.112 | 0.0887 | 0.1315 | 0.1061 | 43.64 | 40.29 | 0.3546 | 0.2891 | 1.22 | 2.79 | 0.4696 | 560.11 | -5.14 | 6.17 | -97.37 | -30.53 | -16.88 | -- |
Data as of Apr 15 2024. Currency figures normalised to Neurocrine Biosciences Inc's reporting currency: US Dollar USD
36.24%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2023 | 10.55m | 10.61% |
| The Vanguard Group, Inc.as of 31 Dec 2023 | 9.57m | 9.62% |
| SSgA Funds Management, Inc.as of 31 Dec 2023 | 4.06m | 4.08% |
| Bellevue Asset Management AGas of 31 Dec 2023 | 2.43m | 2.44% |
| Renaissance Technologies LLCas of 31 Dec 2023 | 1.99m | 2.00% |
| Geode Capital Management LLCas of 31 Dec 2023 | 1.62m | 1.63% |
| Janus Henderson Investors US LLCas of 31 Dec 2023 | 1.55m | 1.55% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2023 | 1.50m | 1.51% |
| T. Rowe Price Associates, Inc. (Investment Management)as of 31 Dec 2023 | 1.40m | 1.41% |
| Point72 Asset Management LPas of 31 Dec 2023 | 1.39m | 1.40% |
More ▼
Data from 31 Dec 2023 - 31 Dec 2023Source: FactSet Research Systems Inc.
